Files in this data supplement:
- Supporting Information: Figures S1-S3, Files S1-S5, Tables S1-S6, and References (PDF, 243 KB)
- Figure S1: Summary of immunostaining in extruded XX adult germlines. (PDF, 121 KB)
- Figure S2: Sex-specific protein expression changes upon chemical reprogramming. (PDF, 174 KB)
- Figure S3: Transcriptome changes during chemical reprogramming. (PDF, 123 KB)
- File S1: puf-8; lip-1 versus puf-8 fbf-1; lip-1 differentially expressed mRNAs. (.xlsx, 42 KB)
- File S2: fbf-1; lip-1 versus puf-8 fbf-1; lip-1 differentially expressed mRNAs. (.xlsx, 57 KB)
- File S3: Comparisons of differentially expressed mRNAs in File S1 (puf-8; lip-1 versus puf-8 fbf-1; lip-1 mRNAs) and File S2 (fbf-1; lip-1 versus puf-8 fbf-1; lip-1 mRNAs). Overlaps of differentially expressed mRNAs with PUF-8 and FBF-1 targets are included. (.xlsx, 893 KB)
- File S4: Transcriptome response to MEK inhibitor. Differentially expressed mRNAs over time with respect to treatment type and time in reprogramming competent and not reprogramming competent genotypes. (.xlsx, 12 KB)
- File S5: mRNA abundance changes upon oocyte differentiation. Differentially expressed mRNAs at 18 hrs of drug treatment in the puf-8; lip-1 reprogramming competent genotype relative to 18-hr DMSO control treatment in that genotype. (.xlsx, 221 KB)
- Table S1: Mapping statistics summary for all Illumina sequencing data collected. (PDF, 117 KB)
- Table S2: GO terms for the 135 mRNAs enriched in puf-8; lip-1 compared to puf-8 fbf-1; lip-1. (PDF, 112 KB)
- Table S3: Comparison of 219 differentially expressed mRNAs between puf-8; lip-1 and puf-8 fbf-1; lip-1 to two lists of germline-enriched mRNAs. (PDF, 143 KB)
- Table S4: Comparison of 350 mRNAs differentially expressed between fbf-1; lip-1 and puf-8 fbf-1; lip-1 to various lists of germline-expressed mRNAs. (PDF, 143 KB)
- Table S5: GO terms for the 335 mRNAs enriched in fbf-1; lip-1 compared to puf-8 fbf-1; lip-1. (PDF, 113 KB)
- Table S6: GO terms for the 928 mRNAs enriched after 18 hours of U0126 treatment in puf-8; lip-1 relative to 18 hours of vehicle DMSO control treatment in puf-8; lip-1. (PDF, 117 KB)